Literature DB >> 23791680

fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations.

Serena Giuntini1, David M Vu, Dan M Granoff.   

Abstract

Meningococci bind human fH to down-regulate complement, which enhances survival of the bacteria in serum. A major fH ligand is the vaccine candidate, factor H-binding protein (fHbp). Although fHbp has been considered an essential meningococcal virulence factor, rarely, invasive isolates with absent fHbp genes or frameshift mutations have been identified. In previous studies fH binding to these isolates was not detected. The aim of the present study was to investigate fH binding and complement evasion by invasive meningococcal serogroup B clinical isolates with absent fHbp genes or frameshift mutations. Four of the seven isolates tested bound human fH by flow cytometry and survived in IgG-depleted human serum. In all four, fH binding was decreased after inactivating the gene encoding NspA. Binding of fH to fHbp and NspA is specific for human fH. To investigate fH-dependent evasion of host defenses, human fH transgenic infant rats, or control littermates negative for human fH, were challenged IP with 10(3)-10(4)CFU of two of the isolates with no detectable fH binding by flow cytometry. At 6h, bacteremia caused by both strains was higher in human fH transgenic rats than in control rats (P<0.002). In conclusion, six of the seven isolates had evidence of fH binding and/or human fH-dependent complement evasion in transgenic rats. In four, NspA was as an alternative fH ligand. fHbp vaccination may select for mutants that do not require fHbp for complement evasion. Inclusion of additional target antigens in vaccines containing fHbp may delay emergence of these mutants.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Complement; Factor H; Neisseria meningitidis; Neisseria surface protein A; NspA; Transgenic rat; Vaccine; fH; fHbp; factor H; factor H-binding protein

Mesh:

Substances:

Year:  2013        PMID: 23791680      PMCID: PMC3756549          DOI: 10.1016/j.vaccine.2013.06.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  46 in total

1.  The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci.

Authors:  Lisa A Lewis; Matthew Carter; Sanjay Ram
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

2.  Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

3.  Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

Authors:  Nicoletta Gossger; Matthew D Snape; Ly-Mee Yu; Adam Finn; Gianni Bona; Susanna Esposito; Nicola Principi; Javier Diez-Domingo; Etienne Sokal; Birgitta Becker; Dorothee Kieninger; Roman Prymula; Peter Dull; Ellen Ypma; Daniela Toneatto; Alan Kimura; Andrew J Pollard
Journal:  JAMA       Date:  2012-02-08       Impact factor: 56.272

4.  Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

5.  Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis.

Authors:  David M Vu; Jutamas Shaughnessy; Lisa A Lewis; Sanjay Ram; Peter A Rice; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-21       Impact factor: 3.441

6.  Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H.

Authors:  Rolando Pajon; Peter T Beernink; Dan M Granoff
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

7.  Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein.

Authors:  Jay Lucidarme; Lionel Tan; Rachel M Exley; Jamie Findlow; Ray Borrow; Christoph M Tang
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

8.  A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Emily M Braga; Qin Liu; Peter A Rice; Sanjay Ram; Dan M Granoff
Journal:  J Immunol       Date:  2011-02-16       Impact factor: 5.422

9.  Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

Authors:  Peter C Richmond; Helen S Marshall; Michael D Nissen; Qin Jiang; Kathrin U Jansen; Maria Garcés-Sánchez; Federico Martinón-Torres; Johannes Beeslaar; Leszek Szenborn; Jacek Wysocki; Joseph Eiden; Shannon L Harris; Thomas R Jones; John L Perez
Journal:  Lancet Infect Dis       Date:  2012-05-07       Impact factor: 25.071

10.  A broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp.

Authors:  David M Vu; Rolando Pajon; Donald C Reason; Dan M Granoff
Journal:  Sci Rep       Date:  2012-03-28       Impact factor: 4.379

View more
  6 in total

1.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.

Authors:  Serena Giuntini; Rolando Pajon; Sanjay Ram; Dan M Granoff
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

3.  Neisseria meningitidis Urethritis Outbreak Isolates Express a Novel Factor H Binding Protein Variant That Is a Potential Target of Group B-Directed Meningococcal (MenB) Vaccines.

Authors:  Yih-Ling Tzeng; Serena Giuntini; Zachary Berman; Soma Sannigrahi; Dan M Granoff; David S Stephens
Journal:  Infect Immun       Date:  2020-11-16       Impact factor: 3.441

Review 4.  How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.

Authors:  R Gasparini; D Panatto; N L Bragazzi; P L Lai; A Bechini; M Levi; P Durando; D Amicizia
Journal:  J Immunol Res       Date:  2015-08-17       Impact factor: 4.818

5.  Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis.

Authors:  Lisa A Lewis; David M Vu; Shreekant Vasudhev; Jutamas Shaughnessy; Dan M Granoff; Sanjay Ram
Journal:  MBio       Date:  2013-10-15       Impact factor: 7.867

6.  The Phosphocarrier Protein HPr Contributes to Meningococcal Survival during Infection.

Authors:  Ana Antunes; Meriem Derkaoui; Aude Terrade; Mélanie Denizon; Ala-Eddine Deghmane; Josef Deutscher; Isabel Delany; Muhamed-Kheir Taha
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.